Anti-TRAIL-R antibody

a technology of anti-trail receptor and antibody, which is applied in the field of anti-trail receptor (trailr) antibodies, can solve the problems of insufficient theoretical support of selectivity, inability to obtain agonistic antibodies with no toxicity, and inability to demonstrate whether or not agonistic antibodies having no toxicity can be obtained
US20050249729A1Inactive Publication Date: 2005-11-10KIRIN BREWERY CO LTD
7 Cites 18 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Applications(United States)
Current Assignee / Owner
KIRIN BREWERY CO LTD
Publication Date
2005-11-10
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

Anti-TRAIL-R1 and R2 antibodies or functional fragments thereof, having at least one property selected from the following (a) to (c) of: (a) having activity to induce apoptosis in carcinoma cells expressing TRAIL-R1 and / or TRAIL-R2; (b) not having effect on normal human cells expressing TRAIL-R1 and / or TRAIL-R2; and (c) not inducing human hepatocyte toxicity, and an anti-TRAIL-R1 and R2 antibodies or functional fragments thereof, having the following properties: having activity to induce apoptosis in carcinoma cells independently of exogenous factors and as a monomer of an antibody.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This a Continuation-In-Part Application of PCT / JP02 / 04816 filed May 17, 2002, and is incorporated herein in its entirety by reference.FIELD OF THE INVENTION

[0002] The present invention relates to an anti-TRAIL receptor (TRAIL-R) antibody recognizing a TRAIL receptor 1 (TRAIL-R1) or a TRAIL receptor 2 (TRAIL-R2), which are cell membrane molecules involved in apoptosis.

[0003] Furthermore, the present invention relates to a prophylactic or therapeutic agent, which contains anti-TRAIL-R antibody as an active ingredient and is used against diseases caused by cells expressing TRAIL-R, and in particular relates to a therapeutic agent used against malignant tumors.

[0004] Furthermore, the present invention relates to a prophylactic or therapeutic agent, which contains anti-TRAIL-R antibody having the activity to induce apoptosis as a monomer independently of exogenous factors as an active ingredient and is used against diseases caused by cells expressing TRAIL-R, and in particular ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More